DF/HCC Program Affiliation

Co-Leader, Translational Pharmacology and Early Therapeutic Trials Program
Member, Neuro-Oncology Program
Member, Lymphoma and Myeloma Program
Member, Gastrointestinal Malignancies Program
Member, Cancer Disparities Program

DF/HCC Associations

Associate Director, Clinical Science, EC
Chair, Clinical Science Coordinating Committee
Member, Center Scientific Council
Scientific Advisor, Cancer Pharmacology Core

Research Abstract

Major interest is in the clinical testing, pharmaco-kinetics, and biochemical pharacology of new anticancer drugs, particulary natural products and signal transdution inhibitors.

Publications

• Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995 Aug; 13(8):1985-94
  PMID: 7636539
• Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995 Aug; 13(8):1995-2004
  PMID: 7636540
• Saikawa Y, Knight CB, Saikawa T, Page ST, Chabner BA, Elwood PC. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J Biol Chem 1993 Mar 5; 268(7):5293-301
  PMID: 7680349